PEAK6 Group’s State Street SPDR S&P Pharmaceuticals ETF XPH Stock Holding History

PEAK6 Group’s Portfolio XPH Stock Details XPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q3	–	Sell	-13,100	Closed	-$680K	–	5247
2014 Q2	$680K	Buy	13,100 +5,400	+70%	+$260K	0.01%	2016
2014 Q1	$360K	Buy	+7,700	New	+$364K	﹤0.01%	2853

Other funds holding XPH

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

UBS Zurich, Switzerland $136B AUM 16.36% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Mather Group Chicago, Illinois $10B AUM 15.14% 1-Year Est. Return

WBG

Wharton Business Group Malvern, Pennsylvania $2.65B AUM 20.73% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

NCM

Niemann Capital Management Stateline, Nevada $788K AUM 23.27% 1-Year Est. Return

Hoxton Financial Shepherdstown, West Virginia $194M AUM 6.21% 1-Year Est. Return

PEAK6 Group's XPH Position: Q3 2014 in Review

PEAK6 Group sold out of State Street SPDR S&P Pharmaceuticals ETF (XPH) in Q3 2014, closing a stake of 13,100 shares — an estimated $680K sold.

PEAK6 Group first reported a position in XPH in Q1 2014 and held it in 2 quarters. The position peaked at $680K in Q2 2014. 74 funds tracked by Wall St. Rank hold XPH as of Q3 2014.

PEAK6 Group reported no remaining State Street SPDR S&P Pharmaceuticals ETF position as of Q3 2014 after selling out during the quarter.
PEAK6 Group sold 13,100 State Street SPDR S&P Pharmaceuticals ETF shares in Q3 2014, an estimated $680K.
PEAK6 Group first reported a position in State Street SPDR S&P Pharmaceuticals ETF in Q1 2014 and held it in 2 quarters.
PEAK6 Group's State Street SPDR S&P Pharmaceuticals ETF position peaked at $680K in Q2 2014.
74 funds tracked by Wall St. Rank held State Street SPDR S&P Pharmaceuticals ETF as of Q3 2014.

Based on PEAK6 Group's 13F filing for Q3 2014, filed 14 Nov 2014.